JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating

With significant upside potential, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) secures a spot on our list of the best small-cap biotech stocks to buy according to analysts.

JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating

On November 12, 2025, Syndax Pharmaceuticals, Inc. saw JPMorgan reduce its price target from $40 to $33, while reiterating its “Overweight” rating. The price target adjustment reflects the investment firm’s revisions to its models in the SMID-cap biotechnology group, as reported by The Fly.

Meanwhile, Syndax Pharmaceuticals, Inc. reported Q3 results on November 3, 2025. The quarter saw a 21% increase in total revenue to $45.9 million, reflecting strong uptake of its lead therapies. In particular, Revuforj was included in NCCN guidelines and received FDA approval for a broader patient population, contributing significantly to the company’s sustained growth. Meanwhile, Niktimvo recorded $200 million in annualized revenue.

Syndax Pharmaceuticals, Inc. ended the quarter with $456 million in cash balances, sufficient to support its ongoing operations and pipeline development through to profitability. The company’s net loss narrowed to $60.7 million, or $0.70 per share, compared to $84.1 million, or $0.98 per share, in Q3 2024. Looking ahead, the company projected total R&D costs of $380 to $385 million for the full year.

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes targeted therapies for rare and difficult-to-treat cancers.

READ NEXT: 7 Best Oil and Gas Penny Stocks to Buy According to Analysts and Billionaire Jacob Rothschild’s RIT Capital Partners: 9 Stocks with Huge Upside Potential.